The role and efficacy of denosumab in the treatment of osteoporosis: an update (Q37826197)

23 August 2017

1 reference

title

The role and efficacy of denosumab in the treatment of osteoporosis: an update (English)

1 reference

23 August 2017

0 references

3

Peter V Giannoudis

0 references

author name string

Ioannis Charopoulos

series ordinal

1

1 reference

23 August 2017

Steve Orme

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

6 January 2011

1 reference

Expert Opinion on Drug Safety

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

205-217

1 reference

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Bone quality--the material and structural basis of bone strength and fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Treatment of osteoporosis with denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Denosumab: anti-RANKL antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Denosumab for joints and bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Emerging treatments for postmenopausal osteoporosis - focus on denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Fully human therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Human antibodies from transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Health economics of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Update on the treatment of post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Salmon calcitonin: a review of current and future therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Teriparatide in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Adherence, patient preference and dosing frequency: understanding the relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.516249

10.1517/14740338.2010.516249

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference